Showing 4441-4460 of 7110 for: Cochrane Systematic Reviews Back
- Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
Cochrane Systematic Reviews, 13-May-2008
Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) in the previous 12 months or two episodes in the last six months. The main factors associated with RUTI in postmenopausal women are vesical prolapse, cy
- Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women
Cochrane Systematic Reviews, 3-Aug-2010
Pelvic organ prolapse is common and can be detected in up to 50% of parous women although many are asymptomatic. Oestrogen preparations are used to improve vaginal thinning (atrophy). It is possible that oestrogens, alone or in conjunction with other inte
- Off-pump versus on-pump coronary artery bypass grafting for ischaemic heart disease
Cochrane Systematic Reviews, 29-Feb-2012
Coronary artery bypass grafting (CABG) is performed both without and with cardiopulmonary bypass, referred to as off-pump and on-pump CABG respectively. However, the preferable technique is unclear.
- Oil-soluble versus water-soluble media for assessing tubal patency with hysterosalpingography or laparoscopy in subfertile women
Cochrane Systematic Reviews, 17-Jul-2008
There has been debate in the literature for more than 40 years as to whether flushing of the Fallopian tubes enhances fertility and whether this presumed therapeutic effect is greater with oil-soluble media than with water-soluble media.
- Olanzapine alone or in combination for acute mania
Cochrane Systematic Reviews, 2-Nov-2008
Olanzapine, an atypical antipsychotic, is used in the treatment of mania both as monotherapy and combined with other medicines.
- Olanzapine for schizophrenia
Cochrane Systematic Reviews, 12-Dec-2012
Olanzapine is an atypical antipsychotic reported to be effective without producing disabling extrapyramidal adverse effects associated with older, typical antipsychotic drugs.
- Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses
Cochrane Systematic Reviews, 4-Aug-2009
People presenting with agitated or violent behaviour thought to be due to severe mental illness may require urgent pharmacological tranquillisation. Several preparations of olanzapine, an antipsychotic drug, are now being used for management of such agita
- Olanzapine in long-term treatment for bipolar disorder
Cochrane Systematic Reviews, 30-Mar-2009
Many patients with bipolar disorder require long-term treatment to prevent recurrence. Antipsychotic drugs are often used to treat acute manic episodes. It is important to clarify whether olanzapine could have a role in long-term prevention of manic and d
- Olanzapine versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 1-May-2013
In many countries of the industrialised world second generation ("atypical") antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generati
- Omalizumab for asthma in adults and children
Cochrane Systematic Reviews, 18-Dec-2013
Asthma is a respiratory (airway) condition that affects an estimated 300 million people worldwide and is associated with significant morbidity and mortality. Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E (IgE). It
- Omega 3 fatty acid for the prevention of cognitive decline and dementia
Cochrane Systematic Reviews, 14-Aug-2012
Evidence from observational studies suggests that diets high in omega-3 long-chain polyunsaturated fatty acids (PUFA) may protect people from cognitive decline and dementia. The strength of this potential protective effect has recently been tested in rand
- Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease
Cochrane Systematic Reviews, 25-Jun-2014
The anti-inflammatory effects of n-3 (omega-3 fatty acids, fish oil) have been suggested to be beneficial in chronic inflammatory disorders such as inflammatory bowel disease. This review is an update of a previously published Cochrane review.
- Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis
Cochrane Systematic Reviews, 27-May-2008
Omega-3 fatty acids (n-3, fish oil) have been shown to have anti-inflammatory properties. Therefore, n-3 therapy may be beneficial in chronic inflammatory disorders such as ulcerative colitis.
- Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration
Cochrane Systematic Reviews, 15-Apr-2015
Evidence from animal models and observational studies in humans has suggested that there is an inverse relationship between dietary intake of omega 3 long-chain polyunsaturated fatty acids (LCPUFA) and risk of developing age-related macular degeneration (
- Omega 3 fatty acids for prevention and treatment of cardiovascular disease
Cochrane Systematic Reviews, 8-Sep-2008
It has been suggested that omega 3 (W3, n-3 or omega-3) fats from oily fish and plants are beneficial to health.
- Omega 6 fatty acids for the primary prevention of cardiovascular disease
Cochrane Systematic Reviews, 13-Nov-2015
Omega 6 plays a vital role in many physiological functions but there is controversy concerning its effect on cardiovascular disease (CVD) risk. There is conflicting evidence whether increasing or decreasing omega 6 intake results in beneficial effects.
- Omega-3 fatty acids for bipolar disorder
Cochrane Systematic Reviews, 2-Nov-2008
Bipolar disorder is a complex psychiatric disorder and is amongst the top thirty causes of worldwide disability. Mood stabilisers are the primary pharmacological intervention, both in the treatment of acute episodes and in prophylaxis. There is, however,
- Omega-3 fatty acids for cystic fibrosis
Cochrane Systematic Reviews, 5-Jan-2016
Studies suggest that a diet rich in omega-3 essential fatty acids may have beneficial anti-inflammatory effects for chronic conditions such as cystic fibrosis. This is an updated version of a previously published review.
- Omega‐3 fatty acids for depression in adults
Cochrane Systematic Reviews, 24-Nov-2021
Major depressive disorder (MDD) is highly debilitating, difficult to treat, has a high rate of recurrence, and negatively impacts the individual and society as a whole. One potential treatment for MDD is n-3 polyunsaturated fatty acids (n-3PUFAs), also kn
- Omega-3 fatty acids for intermittent claudication
Cochrane Systematic Reviews, 3-Jul-2013
Omega-3 fatty acids have been used in the treatment and prevention of coronary artery disease although current evidence suggests they may be of limited benefit. Peripheral arterial disease and coronary artery disease share a similar pathogenesis so omega-
